These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36034977)

  • 1. Cost-effectiveness of olaparib, a PARP inhibitor, for patients with metastatic castration-resistant prostate cancer in China and United States.
    Xu C; Cai J; Zhuang J; Zheng B; Chen L; Sun H; Zheng G; Wei X; Liu M
    Ann Transl Med; 2022 Aug; 10(15):830. PubMed ID: 36034977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer.
    Teppala S; Scuffham PA; Tuffaha H
    Int J Technol Assess Health Care; 2024 Mar; 40(1):e14. PubMed ID: 38439629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    Su D; Wu B; Shi L
    Front Pharmacol; 2020; 11():610601. PubMed ID: 33574757
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance.
    Barqawi YK; Borrego ME; Roberts MH; Abraham I
    J Med Econ; 2019 Nov; 22(11):1202-1209. PubMed ID: 31452414
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US.
    Pan J; Ren N; Ren L; Yang Y; Xu Q
    Sci Rep; 2024 Jun; 14(1):13935. PubMed ID: 38886516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china.
    Shu Y; Liu Y; He X; Ding Y; Zhang Q
    Front Pharmacol; 2022; 13():818579. PubMed ID: 36034834
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients.
    Ten Ham RMT; van Nuland M; Vreman RA; de Graaf LG; Rosing H; Bergman AM; Huitema ADR; Beijnen JH; Hövels AM
    Value Health; 2021 Jan; 24(1):121-128. PubMed ID: 33431146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic
    Li N; Zheng H; Huang Y; Zheng B; Cai H; Liu M
    Front Pharmacol; 2021; 12():632818. PubMed ID: 33959007
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance.
    Zhang PF; Xie D; Li Q
    BMC Cancer; 2021 Jan; 21(1):35. PubMed ID: 33413230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer.
    Gong CL; Hay JW
    J Natl Compr Canc Netw; 2014 Oct; 12(10):1417-25. PubMed ID: 25313181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
    Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
    Ming J; Wu Y; Han R; Xu X; Waldeck R; Hu S
    Adv Ther; 2023 Mar; 40(3):1087-1103. PubMed ID: 36630046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial.
    Zhan M; Zheng H; Yang Y; He Z; Xu T; Li Q
    Cancer Manag Res; 2020; 12():12919-12926. PubMed ID: 33364840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran.
    Goudarzi Z; Lotfi F; Najafpour Z; Hafezi A; Zakaria MA; Keshavarz K
    BMC Urol; 2024 Feb; 24(1):45. PubMed ID: 38378521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer.
    Zhong L; Tran AT; Tomasino T; Nugent E; Smith JA
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1219-1228. PubMed ID: 30479195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression.
    Huang X; Lin D; Lin S; Luo S; Huang X; Deng Y; Weng X; Huang P
    Clin Breast Cancer; 2023 Jul; 23(5):508-518. PubMed ID: 37085377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in
    Li Y; Lin S; Zhong L; Luo S; Huang X; Huang X; Dong L; Xu X; Weng X
    Pharmacogenomics; 2021 Aug; 22(13):809-819. PubMed ID: 34517749
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer in Japan.
    Okumura H; Inoue S; Naidoo S; Holmstrom S; Akaza H
    Jpn J Clin Oncol; 2021 Aug; 51(8):1319-1329. PubMed ID: 34037235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective.
    Chiang CL; So TH; Lam TC; Choi HCW
    Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):108-115. PubMed ID: 31273290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China.
    Xu X; Fang N; Li H; Liu Y; Yang F; Li X
    Ann Transl Med; 2021 May; 9(9):760. PubMed ID: 34268373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.